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Abstract
Introduction Tertiary hyperparathyroidism (tHPT), i.e., persistent HPTafter kidney transplantation, affects 17–50% of transplant
recipients. Treatment of tHPT is mandatory since persistently elevated PTH concentrations after KTx increase the risk of renal
allograft dysfunction and osteoporosis. The introduction of cinacalcet in 2004 seemed to offer a medical treatment alternative to
parathyroidectomy (PTx). However, the optimal management of tHPT remains unclear.
Methods A retrospective analysis was performed on patients receiving a kidney transplantation (KT) in two academic centers in
the Netherlands. Thirty patients undergoing PTx within 3 years of transplantation and 64 patients treated with cinacalcet 1 year
after transplantation for tHPTwere included. Primary outcomes were serum calcium and PTH concentrations 1 year after KTand
after PTx.
Results Serum calcium normalized in both the cinacalcet and the PTx patients. PTH concentrations remained above the upper
limit of normal (median 22.0 pmol/L) 1 year after KT, but returned to within the normal range in the PTx group (median
3.7 pmol/L). Side effects of cinacalcet were difficult to assess; minor complications occurred in three patients. Re-exploration
due to persistent tHPTwas performed in three (10%) patients.
Conclusion In patients with tHPT, cinacalcet normalizes serum calcium, but does not lead to a normalization of serum PTH
concentrations. In contrast, PTx leads to a normalization of both serum calcium and PTH concentrations. These findings suggest
that PTx is the treatment of choice for tHPT.
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Introduction
Hyperparathyroidism (HPT) is a state of overproduction of
parathyroid hormone (PTH) due to over activity of one or
more of the parathyroid glands [1]. Secondary HPT (sHPT)
frequently complicates chronic kidney disease (CKD). CKD
causes phosphate retention, hypovitaminosis D [1,25-(OH)2-
D], and hypocalcemia, leading to stimulation of the parathy-
roid glands and increased PTH production. Secondary HPT
occurs in 25–30% of patients with end-stage renal disease
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(ESRD) and is associated with severe bone mineral disease
[2]. Importantly, sHPT is also associated with increased car-
diovascular morbidity [2] and mortality [3, 4]. The first line of
treatment of sHPT used to consist of calcium and vitamin D
supplementation followed by either medical therapy using
calcimimetics [5] or surgical treatment by parathyroidectomy
(PTx) [6]. For dialysis patients requiring PTH-lowering ther-
apy, the current recommendation is to treat with
calcimimetics, calcitriol or vitamin D analogs, or a combina-
tion of these therapies [7].
Secondary HPT can be corrected by a successful kidney
transplantation (KT) [8]. Nevertheless, 17–50% of patients
who receive a kidney transplant remain in a state ofHPT1 year
after KT [9–11]. This is referred to as tertiary or post-renal
transplantation HPT (tHPT), which is characterized by exces-
sive and autonomous production and excretion of PTH [8,
12]. In general, the PTH concentration rapidly declines within
the first 3 months after KT and then continues to decline more
gradually over the course of the next 9 months. One year after
transplantation, PTH concentrations are unlikely to decline
further [9–11].
As tHPT increases the risk of renal allograft dysfunction and
renal allograft loss [13, 14], osteoporosis [15], and bone frac-
tures [16], adequate management is essential. Introduced in
2004, the calcimimetic drug cinacalcet (Mimpara®, Amgen
Inc., Thousand Oaks, CA, USA) is frequently used for the
treatment of ESRD-related HPT [17, 18]. Cinacalcet suppresses
the production of PTH by increasing the sensitivity of the
calcium-sensing receptor of the parathyroid gland to calcium
[19]. The United States Food and Drug Administration and the
European Medicines Agency have approved cinacalcet for the
treatment of secondary but not tertiary HPT. This is despite a
number of small non-randomized studies demonstrating the
safety of cinacalcet in tHPT, with gastrointestinal intolerance
being the most common side effect [20].
Before the introduction of cinacalcet, the only treatment
option for patients with tHPT was parathyroidectomy (PTx)
[21]. This surgical procedure involves either subtotal or total
PTx (with or without auto-transplantation), which are both
effective and safe procedures [22, 23]. In sHPT, PTx was even
associated with a lower risk of major cardiovascular events
after surgery [24].
The effect of cinacalcet on cardiovascular morbidity and
mortality has recently been studied in the EVOLVE trial [25].
This study in dialysis patients demonstrated that treatment
with cinacalcet, despite lowering serum calcium in a sufficient
way, does not reduce the risk of major cardiovascular events
or death. In an additional meta-analysis of randomized con-
trolled trials, cinacalcet did not improve overall survival of
dialysis patients [26]. Consequently, the Australian
Government stopped the reimbursement of cinacalcet
(https://www.nps.org.au/radar/articles/sensipar-cinacalcet-
pbs-listing-to-be-deleted#article).
The only randomized controlled trial comparing the effects
of PTx and cinacalcet in the treatment of tHPT included 30
patients and concluded that 66% of patients treated with
cinacalcet achieved normocalcemia compared with 100% af-
ter PTx [27]. As this is the only trial comparing these treat-
ment modalities and having a small sample size, the optimal
management strategy for tHPT remains unclear and additional
studies including larger patient numbers are needed. In this
study, the outcomes of treatment with PTx or cinacalcet for
tHPT were compared in a larger cohort of patients derived
from the data of two academic centers.
Methods
Study population
All patients who received a first KT at one of the two partic-
ipating university medical centers between 1994 and 2015 and
had a history of PTx or calcimimetic use, both before and after
KT, were included. Their demographic and clinical data were
stored in a central database. This study was approved by the
institutional review boards of all participating centers.
Inclusion criteria for this study were a diagnosis of tHPT,
age ≥ 18 years at the time of KT, and the availability of serum
calcium and serum PTH concentrations after KT. Tertiary
HPT was defined as the need for PTx within 3 years after
KT or the (continuous) need of cinacalcet treatment at month
12 after KT. Patients with previous parathyroid surgery were
excluded. Two groups were identified. Group 1 (cinacalcet
group) consisted of patients who received treatment with
cinacalcet at month 12 after their first KT without a history
of PTx. Group 2 (PTx group) consisted of patients who
underwent a PTx within 3 years of their first KT. Outcomes
of the PTx group in the first year after KT are presented for
patients who had not undergone PTx at the set time points.
The primary outcomes were serum calcium and PTH con-
centration 1 year after KT and 1 year after PTx. Secondary
outcomes were the use of co-medication (calcium supplemen-
tation, vitamin D supplementation, cinacalcet) after KT and
PTx and complications after KT and PTx.
Data collection
Electronic patient files were reviewed for patient data.
Baseline characteristics were gender, age, primary kidney dis-
ease, type and duration of dialysis, medication use, and rele-
vant co-morbidity (e.g., diabetes mellitus and cardiovascular
disease).
KT data included donor type and age, ischemia times, post-
operative complications graded by the Clavien-Dindo scale
[28], delayed graft function (defined as the need for dialysis
in first week after KT), primary non-function, biochemical
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parameters until 5 years after KT (calcium, phosphate, albu-
min, creatinine, alkaline phosphatase, and PTH), and medica-
tion use after KT (calcium or vitamin D supplementation,
phosphate binders, and calcimimetics). Data on the use of
diuretics were not systematically collected.
PTx data included type of the surgical procedure (total or
subtotal), complication rate, imaging before PTx, laboratory
data before PTx until 5 years after PTx (calcium, phosphate,
albumin, creatinine, alkaline phosphatase and PTH), and med-
ication use after PTx (calcium or vitamin D supplementation,
phosphate binders, and calcimimetics). The decision to per-
form a total or subtotal parathyroidectomy was at the sur-
geons ’ discre t ion . There was no rout ine use of
neuromonitoring and no routine post-operative laryngoscopy.
Serum calcium concentrations were adjusted for albumin
according to the following formula: adjusted total calcium
(mmol/L) = measured calcium (mmol/l) + (0.025 × (40 − [al-
bumin (g/L)])). The reference value for calcium was 2.20–
2.60 mmol/L. The reference value for PTH was 1.4–
7.3 pmol/L. PTH values were measured with the Vitros
ECi assay (Ortho Diagnostics) and with the Roche Cobas
assay (Roche). The reference values for creatinine were
65–115 μmol/L for male patients and 55–90 μmol/L for
female patients. Persistent post-operative hypocalcemia
was defined as the need for calcium supplementation
6 months after PTx.
Statistical analysis
Distribution was assessed using the Shapiro-Wilk test for nor-
mality. Continuous variables are presented as median with
interquartile range (IQR), and categorical variables were de-
scribed as count (n) and percentage (%). Differences between
the two groups were analyzed using the Mann-WhitneyU test
for continuous variables and the Pearson chi-square or
Fisher’s exact test for nominal variables. The Wilcoxon
signed-rank test was used to compare the differences between
time points. Statistical analysis was performed using IBM
SPSS Statistics 21 software (IBM Corp., Chicago, IL, USA).
Results
Study population
A total of 277 patients were included in our database. A total
of 94 patients (33.9%) were included in this study based on the
abovementioned inclusion and exclusion criteria. Thirty pa-
tients were included in the PTx group whereas 64 patients
were included in the cinacalcet group. A flowchart of patient
selection is depicted in Fig. 1.
Baseline characteristics
Patient characteristics at the time of KT are listed in Table 1.
Median age of all patients at time of KTwas 56.0 years (45.8–
62.0). Themedian age of PTx patients at time of KTwas lower
(52.5 years (35.8–57.3)) compared with that of patients using
calcimimetics (59.0 years (50.0–64.0), p = 0.034). The medi-
an duration of dialysis before KT was 42.5 months (21.0–
63.0); 43.6% of patients were female and 25.5% of patients
had a history of diabetes mellitus. At the time of KT, 81.3% of
patients received phosphate binders, 66.0% received vitamin
D supplements, 23.3% received calcium supplementation, and
45.7% received calcimimetics. Of all KT, 55.3% was per-
formed with a deceased donor kidney. Delayed graft function
occurred in 27.7% of patients. Cold and warm ischemia times
were significantly longer in the PTx group (23 versus 15 h,
p = 0.023, and 29 versus 23.5 min, p = 0.048, respectively).
Outcomes after kidney transplantation
Pre- and post-KT laboratory values are listed in Table 2.
Serum calcium concentrations were higher in the PTx group
preoperatively (2.51 versus 2.42 mmol/L). There was a sig-
nificant increase in serum calcium concentrations at 3 months
after transplantation in both groups (cinacalcet group: p =
0.002; PTx group: p = 0.001), but this did not persist after
Patients included in
database
277
Patients with
history of PTx
n = 131
Patients with
cinacalcet use
n = 146
Patients with PTx
after KTx
n = 50
Patients with PTx <3
years after KTx
n = 30
Patients with
cinacalcet use after
KTx
n = 118
Patients with
cinacalcet use 1
year after KTx
n = 64
Fig. 1 Flowchart of patient selection
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6 months in the cinacalcet group (p = 0.148). PTx patients not
yet operated in the first post-transplant year remained hyper-
calcemic during the first post-transplant year. Calcium con-
centrations in the PTx group were higher at all time points,
with a median calcium of 2.76 mmol/L 1 year after
transplantation.
Median PTH concentrations were significantly higher in
the PTx group before KT (90.0 versus 54.4 pmol/L, p =
0.013) and 3 months after transplantation (34.3 versus
22.7 pmol/L, p = 0.007). Both groups showed a decline in
serum PTH concentrations after kidney transplantation. In
the PTx group, this decline was statistically significant at
6 months after transplantation (p = 0.012) but not observed
at 1 year post KT. In the cinacalcet group, PTH concentrations
declined significantly after KT at all time points (p < 0.001 at
all time points). In the PTx group, 10.3% of patients used
cinacalcet 1 year after transplantation. In total, 34.5% of pa-
tients in the PTx group used vitamin D analogs 1 year after
transplantation, whereas 14.1% of patients in the cinacalcet
group used vitamin D analogs.
Parathyroidectomy
The characteristics of the patients who underwent PTx are
listed in Table 3.Median age at the time of PTxwas 54.5 years;
66.7% of patients were classified as ASA III. Twelve patients
(40%) underwent a PTx in the first year, and 18 underwent
(60%) PTx in the second or third year after KT. Subtotal
Table 1 Baseline characteristics
Cinacalcet group PTx group p value
Characteristic
No. of patients 64 30
Age at start dialysis (years) 53.5 (45.3–61.8) 49.5 (32.8–55.8) 0.034
Sex (female) 27 (42.2) 14 (46.7) NS
Charlson score 3 (2–5) 3 (2–4) NS
Dialysis type NS
- No dialysis 12 (18.8) 2 (6.7)
- Peritoneal dialysis 19 (29.7) 11 (36.7)
- Hemodialysis shunt 29 (45.3) 15 (50.0)
- Hemodialysis line 4 (6.3) 2 (6.7)
Duration of dialysis (months) 42.5 (21.3–67.5) 42.5 (18–54.8) NS
History of diabetes 15 (23.4) 9 (30.0) NS
Use of medication before KT
- Vitamin D 47 (74.6) 15 (53.6) NS
- Phosphate binders 52 (82.5) 22 (78.6) NS
- Calcium suppletion 12 (19) 9 (32.1) NS
- Cinacalcet 38 (60.3) 5 (17.2) < 0.001
Transplant characteristics
Age at transplantation (years) 59.0 (50.0–64.0) 52.5 (35.8–57.3) 0.034
Donor type NS
- DCD 17 (26.6) 8 (26.7)
- DBD 18 (28.1) 9 (30.0)
- LR 13 (20.3) 6 (20.0)
- LUR 16 (25.0) 7 (23.3)
Complications NS
- Grade 2 16 (25.0) 9 (30.0)
- Grade 3 6 (9.4) 6 (20)
Delayed graft function 19 (29.7) 7 (23.3) NS
Primary non-function 0 (0) 2 (6.7) NS
Cold ischemia time (h) 15 (12–19.8) 21 (16–24) 0.023
Warm ischemia time (min) 23.5 (18–32) 29 (22–35) 0.048
Data are expressed as median (interquartile range) or n (%)
PTx parathyroidectomy
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parathyroidectomy was performed in 83.3% of patients. Re-
exploration due to persistent tHPT was performed in three
(10%) patients. Initial operation was subtotal PTx in two pa-
tients and a less than subtotal PTx in one patient. Two patients
required a second operation within the first post-operative
month and one 10months after initial surgery due to persistent
HPT. There were no post-operative hematomas requiring re-
exploration, no recurrent laryngeal nerve injuries, and no post-
operative cardiovascular events, and there was no post-
operative mortality. Post-operative hypocalcemia was appar-
ent in 40% of patients.
Laboratory values before and after PTx are listed in
Table 4. Serum calcium concentrations declined signifi-
cantly after PTx; no patients were hypercalcemic 1 year
after PTx. PTH concentrations declined significantly after
PTx and were in the reference range. Vitamin D analogs
were used in 42.9% of patients 1 year after PTx. One
patient used cinacalcet (3.6%) after PTx. A total of 40%
of patients used calcium supplementation 6 months after
surgery.
Discussion
This study describes a cohort of patients treated for tHPT,
either by PTx or by cinacalcet. After PTx, patients were
normocalcemic and PTH concentrations normalized.
Treatment with cinacalcet resulted in normocalcemia but not
in normalization of PTH concentrations. After kidney trans-
plantation, the PTH concentrations declined in both groups,
but were higher in the group of patients that would still under-
go PTx. Median PTH concentrations in both groups remained
above the upper limit of normal (7.3 pmol/L) up to 12 months
after transplantation. In the cinacalcet group, the serum calci-
um concentrations remained normal, whereas patients who
would undergo PTx became hypercalcemic. After parathy-
roidectomy, both serum calcium concentrations and PTH con-
centrations were in the normal range. No differences in renal
transplant function were observed, despite significantly longer
ischemia times in the PTx group.
These findings raise questions about the efficacy of off-
label use of cinacalcet in the treatment of tertiary
Table 2 KT outcomes
Group 1 (cinacalcet) Group 2 (PTx) p value Number at risk PTx
N 64 30
Corrected calcium (mmol/L)
Pretransplantation 2.42 (2.23–2.54) 2.51 (2.33–2.69) 0.030 30
3 months 2.50 (2.36–2.63) 2.84 (2.64–2.90) < 0.001 30
6 months 2.44 (2.34–2.59) 2.79 (2.65–2.85) < 0.001 25
1 year 2.40 (2.23–2.49) 2.76 (2.56–2.90) < 0.001 18
PTH (pmol/L)
Pretransplantation 54.4 (29.7–91.0) 90.0 (61.4–156.4) 0.013 30
3 months 22.7 (14.0–32.7) 34.3 (25.3–80.3) 0.007 30
6 months 18.2 (14.0–27.9) 26.3 (16.3–55.1) 0.056 25
1 year 22.0 (13.7–33.1) 29.8 (15.3–57.1) NS 18
Creatinine (μmol/L)
3 months 119 (103–163) 126 (112–179) NS 30
6 months 125 (100–164) 118 (100–142) NS 25
1 year 122 (101–161) 127 (102–173) NS 18
Use of vitamin D
Pretransplantation 47 (74.6) 15 (53.6) NS 30
3 months 15 (26.8) 3 (10.3) NS 30
6 months 9 (15.8) 2 (8.3) NS 25
1 year 9 (14.1) 2 (11.1) NS 18
Use of cinacalcet
Pretransplantation 38 (60.3) 5 (17.2) < 0.001 30
3 months 38 (67.9) 2 (6.9) < 0.001 30
6 months 50 (87.7) 3 (12.5) < 0.001 25
1 year 64 (100) 3 (17.6) < 0.001 18
Data are expressed as median (interquartile range) or n (%)
PTx parathyroidectomy
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hyperparathyroidism. Adequate control of PTH in the post-
transplant period is paramount given the increased risk of
allograft dysfunction, allograft loss 13, 14, all-cause mortality
30, fractures, and osteoporosis [15, 16]. These reservations
concerning the treatment of tHPT with cinacalcet are also
supported by a study of Cruzado and colleagues [27]. In this
study, patients with tHPTwere randomized between PTx and
cinacalcet therapies. The primary outcome was achievement
of normocalcemia after 1 year. In patients with a PTx, 100%
achieved normocalcemia, in comparison with 67% of patients
after treatment with cinacalcet.
Patients with ESRD are fragile as shown from high ASA
scores, and it is therefore understandable that there is some
reluctance to refer patients for surgical treatment [29]. Still, in
this study, surgical complications after PTx were rare.
Cardiovascular events did not occur and only one patient de-
veloped pneumonia. There were no clinical recurrent laryn-
geal nerve injuries, although only patients with dysphonia
underwent laryngoscopy. This is comparable with the results
of another large Dutch study [30]. The rate of post-operative
hypocalcemia in this study was 40% at 6 months. This was
higher than expected in view of results from older studies [31,
32]. However, patients in our PTx group were mainly hyper-
calcemic patients, who more frequently have hungry bone
syndrome and require longer calcium supplementation. Post-
operative increase in serum creatinine levels was seen at
3 months after PTx. At 12 months, there were no statistical
differences compared with baseline value. A temporary de-
cline in graft function is seen often after PTx; however, it does
not influence graft survival [33]. Overall, PTx is a safe proce-
dure, even in this fragile population [22, 30, 32, 34].
In our study, both total and subtotal parathyroidectomies
were performed, which are both safe and effective procedures
[23]. A randomized controlled trial comparing these proce-
dures in sHPT found similar results for both techniques with
a slightly higher rate of recurrence after subtotal parathyroid-
ectomy [31]. Such a study has not been performed for tHPT
[35]. However, favorable results have been reported
concerning subtotal parathyroidectomy for tHPT, albeit not
in an RCT [22, 27]. Considering that the underlyingmetabolic
disorders responsible for the occurrence of HPT have been
corrected after successful transplantation, we prefer subtotal
parathyroidectomy. This procedure is associated with a lower
risk of post-operative hypocalcemia and persistent hypopara-
thyroidismwhile recurrences are unlikely due to the metabolic
changes.
Table 3 PTx characteristics
Characteristic PTx group
Age at parathyroidectomy (years) 54.5 (36.8–59.3)
ASA classification
II 10 (33.3)
III 20 (66.7)
Preoperative imaging
No imaging 18 (62.1)
Ultrasound 4 (13.8)
MIBI scan 3 (10.3)
Ultrasound and MIBI scan 4 (13.8)
Type of PTx
Total parathyroidectomy 3 (10.0)
Subtotal parathyroidectomy 25 (83.3)
Other 2 (6.7)
Complications
Post-operative hypocalcemia 12 (40)
Recurrent laryngeal nerve damage 0 (0)
Surgical site infection 1 (3.3)
Pneumonia 1 (3.3)
ICU admission 1 (3.3)
Mortality 0 (0)
Re-exploration 3 (10)
Weight of parathyroid glands (g) 1.9 (1.2–3.0)
Data are expressed as median (interquartile range) or n (%)
PTx parathyroidectomy
Table 4 PTx outcomes
PTx group p value^
Corrected calcium (mmol/L)
Preoperative 2.76 (2.62–3.04)
3 months 2.30 (2.23–2.43) < 0.001
6 months 2.31 (2.16–2.37) < 0.001
1 year 2.34 (2.14–2.41) < 0.001
PTH (pmol/L)
Preoperative 35.5 (20.3–62.8)
3 months 9.0 (4.7–20.8) 0.001
6 months 9.5 (3.3–22.6) 0.009
1 year 3.7 (1.2–9.3) 0.012
Creatinine (μmol/L)
Preoperative 122 (104–173) NS
3 months 141 (107–177) 0.015
6 months 147 (121–214) NS
1 year 140 (107–214) NS
Use of vitamin D
3 months 14 (50.0)
6 months 15 (53.6)
1 year 12 (42.9)
Use of cinacalcet
3 months 1 (3.6)
6 months 1 (3.6)
1 year 1 (3.6)
Data are expressed as median (interquartile range) or n (%)
PTx parathyroidectomy
^p value: compared with preoperative measurements
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This study was not designed to evaluate cost-effectiveness
and therefore we cannot report on this. To date, no studies
evaluating cost-effectiveness in tertiary HPT have been pub-
lished. However, for sHPT, it was demonstrated that uncon-
trolled HPT increases the economic burden due to higher med-
ication and hospitalization costs [36], and PTx is more cost-
effective than treatment with cinacalcet after 15 months of
treatment [37]. Considering the increasing survival of kidney
transplant patients, one could assume PTx to be even more
cost-effective in patients with tHPT, especially when consid-
ering that in dialysis patients, the cinacalcet costs for one
QALYexceed $ 100,000 [38].
Some limitations of this study should be addressed. First,
the retrospective designmakes this study susceptible to bias as
demonstrated by the difference at baseline between our
groups. There is no clear guideline on indications for PTx,
so indications may differ between participating centers. The
PTx group was younger and had higher PTH levels at base-
line. But though the baseline PTH levels were higher in the
PTx group, the effect was more profound compared with that
in the cinacalcet group.
Second, in the Netherlands, KT patients are followed in the
transplant center in the first year after transplantation. If un-
eventful, follow-up will then be performed at the referring
hospital, with only annual follow-up at the transplant center.
Thus, some outcome data after the first post-transplant year
was incomplete. Only the short-term outcomes of the first
post-transplant year have therefore been reported.
Third, outcomes in this study are primarily of biochemical
nature. Comparison of clinical outcome parameters (e.g., car-
diovascular disease or bone mineral density values and frac-
ture risks) was not possible due to lack of BMDmeasurements
and lack of follow-up at our centers.
A minority of patients in our cohort received vitamin D
supplementation, recommended in the KDIGO guideline
CKD-MBD as a first-line treatment for HPT since 2003 [6].
However, our cohort encompasses over 20 years of treatment,
including the years up to 2003. This is not applicable for the
group of patients treated with cinacalcet, as cinacalcet was
registered after the first KDIGO guideline. This
undertreatment with vitamin D might have resulted in over-
treatment with cinacalcet in the cinacalcet group. Vitamin D
levels would have been important to consider, as vitamin D
stimulates intestinal calcium reabsorption which, in turn, in-
hibits the release of PTH from the parathyroid through nega-
tive feedback to the calcium-sensing receptor. As a conse-
quence, higher vitamin D levels would lead to higher calcium
and suppressed PTH levels and vice versa. Unfortunately, vi-
tamin D levels were not available for our study. However, the
majority of patients (66.0%) used vitamin D supplements at
baseline, and there was no significant difference in vitamin D
supplement use among both groups. Moreover, the strong
PTH decline in the PTX group seems independent of vitamin
D supplement use, which remained more or less stable during
the first year post-PTx (Table 4). Fourth, the higher percentage
of patients that reached normocalcemia in the PTx group
(100%), compared with the cinacalcet-treated group (67%),
in combination with the stronger effect on PTH levels in the
PTX group is unlikely to be explained by differences in vita-
min D levels between both groups. Lastly, in the present study,
side effects of cinacalcet were not reported. These outcomes
are often not reported in patient charts, although reporting has
been reliable in the EVOLVE trial. In this RCT, 46% of the
subjects reported side effects and 18.1% of patients
discontinued the treatment [25] In other studies with
cinacalcet, the rate of side effects was unfortunately not re-
ported [39, 40].
In conclusion, treatment with cinacalcet in patients with
tHPT normalized serum calcium concentrations, but did not
lead to normalization of PTH concentration. After parathy-
roidectomy, both calcium and PTH normalized in the PTx
group. Due to the heterogeneity of the two study groups and
the retrospective design of this study, definitive recommenda-
tions for daily practice cannot be made. Given the effects of
high PTH concentrations on renal allograft survival, we favor
PTx in all patients with tHPT. Future prospective randomized
studies with long-term follow-up are needed to define the role
of surgery in patients with tHPTconsidering clinical outcomes
and economic benefits.
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